PLUS1
7.38
0.49 (7.11%)
0.49 (7.11%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vaxart Inc | VXRT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.49 | 7.11% | 7.38 | 10:15:40 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 7.09 | 7.58 | 7.10 | 6.89 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 7.37 | 7.39 | 0.02 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 11,411 | 4,515,787 | $ 7.30 | $ 32,985,139 | 25,462,468 | 0.2543 - 17.49 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:15:38 | 2,000 | $ 7.38 | USD |
Vaxart Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 805.91M | 109.20M | 83.27M | $ 9.86M | $ - | -0.79 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Vaxart News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/23/2020 | 13:15 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/15/2020 | 06:18 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/27/2020 | 08:18 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/27/2020 | 08:16 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 8/27/2020 | 08:10 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/14/2020 | 16:23 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/12/2020 | 16:32 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VXRT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.10 | 9.2921 | 6.23 | 8.19 | 25,491,457 | -0.72 | -8.89% |
| 1 Month | 6.30 | 9.43 | 4.51 | 7.21 | 34,107,447 | 1.08 | 17.14% |
| 3 Months | 7.12 | 17.49 | 4.51 | 10.18 | 30,105,135 | 0.26 | 3.65% |
| 6 Months | 1.64 | 17.49 | 1.50 | 8.55 | 21,197,967 | 5.74 | 350.0% |
| 1 Year | 0.50 | 17.49 | 0.2543 | 7.12 | 13,478,877 | 6.88 | 1,376.0% |
| 3 Years | 7.15 | 17.49 | 0.2543 | 6.97 | 4,937,621 | 0.23 | 3.22% |
| 5 Years | 21.78 | 25.41 | 0.2543 | 7.02 | 3,004,005 | -14.40 | -66.12% |
Vaxart Description
| Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus. |
